X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The company intends to use the net proceeds to fund the development of AR882, a highly potent and selective next-gen URAT1 inhibitor delivered in a once daily immediate release oral capsule, being developed for the treatment of gout.
Lead Product(s): AR882
Therapeutic Area: Rheumatology Product Name: AR882
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Guangrun Health Industry
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing July 12, 2023
Details:
Company presented AR882, a potent and Selective Uricosuric agent, which have shown to be a promising new option for gout patients as a safe and potent urate lowering medication even in those with kidney impairment.
Lead Product(s): AR882
Therapeutic Area: Nephrology Product Name: AR882
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
